13 assets in Thymic Carcinoma

Therapeutic assets addressing Thymic Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Thymic Carcinoma	Beijing Biotech	P2	B (63)
Fludarabine Thymic Carcinoma	Beijing Biotech	P2	B (62)
Domvanalimab Thymic Carcinoma	Hospices Civils de Lyon	P2	CCC (53)
Zimberelimab Thymic Carcinoma	Hospices Civils de Lyon	P2	CCC (53)
Avelumab Thymic Carcinoma	National Cancer Institute (NCI)	P2	CCC (48)
Eb-Car30-Nk Thymic Carcinoma	Beijing Biotech	P1/2	CC (45)
Eb-Car5-Nk Thymic Carcinoma	Beijing Biotech	P1/2	CC (45)
Eb-Carmsln-Nk Thymic Carcinoma	Beijing Biotech	P1/2	CC (45)
Fludeoxyglucose Thymic Carcinoma	Jonsson Comprehensive Cancer Center	P1	CC (43)
kfa115 Thymic Carcinoma	Novartis Pharmaceuticals	P1	CC (43)
Pembrolizumab Thymic Carcinoma	Novartis Pharmaceuticals	P1	CC (43)
Rimiducid Thymic Carcinoma	Beijing Biotech	P1/2	CC (43)
cd70-targeting car-t cells Thymic Carcinoma	Chongqing Precision Biotech Co., Ltd	P1	CC (41)